Dyadic Applied BioSolutions and UK‑based Opes Diagnostics Limited announced a commercial partnership that will bring Dyadic’s recombinant human transferrin, bovine transferrin, human fibroblast growth factor (FGF) and bovine FGF to the serum‑free cell‑culture media market and related life‑science applications.
The agreement gives Opes Diagnostics access to Dyadic’s portfolio of animal‑free proteins, while Dyadic retains the right to sell directly and to partner with other global distributors. Opes will use its established commercial relationships in Europe, Israel and Asia to accelerate market entry for the four proteins, which are critical components for research, diagnostics, cultured‑meat production and biomanufacturing.
This partnership aligns with Dyadic’s strategic pivot toward commercialization of its C1 and Dapibus microbial platforms, which enable high‑yield, animal‑free protein production. The serum‑free media market was valued at roughly $1.97 billion in 2024 and is projected to reach $4.08 billion by 2034, while the cultured‑meat market is expected to grow into the billions by 2030. By partnering with a diagnostics company that already serves these segments, Dyadic positions itself to capture early revenue streams and validate its platforms in a high‑growth environment.
Opes Diagnostics brings deep market experience and a network of customers in the target regions. Its existing commercial relationships will help Dyadic overcome the typical barriers of entry for a new protein supplier, such as regulatory approvals, supply‑chain integration and customer trust. The partnership therefore accelerates Dyadic’s transition from a research‑focused company to a commercial player in the life‑sciences protein market.
Joe Hazelton, President and COO of Dyadic, said the collaboration “supports our commercial objectives by extending our recombinant protein portfolio in target markets with a partner that has strong, existing sector relationships.” He added that Opes’ market presence “will help drive adoption of Dyadic’s cell‑culture media products into expanding markets and further our shift from primarily development activities to broader commercial engagement.”
While the financial terms of the agreement were not disclosed, the partnership is expected to generate early revenue streams for Dyadic and to validate its C1 and Dapibus platforms in a high‑growth segment. The deal underscores Dyadic’s commitment to delivering animal‑free proteins to the rapidly expanding serum‑free media and cultured‑meat markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.